Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography

NCT ID: NCT02282163

Last Updated: 2020-07-13

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 13 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-10-31
• Study Completion Date: 2018-08-31

Brief Summary

Safety and Efficacy Study in pediatric subjects aged 9 to 17 years of age with suboptimal LV EBD on non-contrast 2D echocardiography. Imaging modalities that are used throughout the study in pediatric subjects represented those utilized in routine clinical practice in adults.

Detailed Description

This was a Phase III, multicenter, open-label study that was to be conducted at approximately 7-12 sites in the United States, Canada and Europe in pediatric patients with suboptimal LV EBD on non-contrast 2D transthoracic echocardiography. It was estimated that 92 patients were to be enrolled to provide 73 evaluable patients.

Three cardiologists unaffiliated with enrolling centers (blinded readers), blinded to the patient's identity and clinical profile were to independently evaluate the echocardiograms. The efficacy analysis was primarily based on the blinded reader evaluations.

Imaging modalities that are used throughout the study in pediatric subjects represented those utilized in routine clinical practice in adults.

One of the sites participating in this study was to be asked to consent a subset of patients for additional blood sampling for analysis of SF6 concentration in blood from a total of 6 patients (3 males and 3 females) in the age group 9 up to 12 years of age and 6 patients (3 males and 3 females) in the age of >12 up to and including 17 years.

The current study was designed to assess the efficacy of Lumason-enhanced echocardiography in pediatric patients.

Conditions

Heart Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Lumason

All patients were administered, Lumason (sulphur hexafluoride lipid-type A microspheres) an ultrasound contrast agent as a single 0.03 mL/kg bolus injection during echocardiography.

Group Type: EXPERIMENTAL

sulphur hexafluoride lipid-type A microspheres

Intervention Type: DRUG

Ultrasound imaging contrast agent

Interventions

sulphur hexafluoride lipid-type A microspheres

Ultrasound imaging contrast agent

Intervention Type: DRUG

Other Intervention Names

Lumason; SonoVue

Eligibility Criteria

Inclusion Criteria

• Provide Written informed consent from parent(s) or legal guardian
• Provide assent when required according to local regulations
• Suspected of having cardiac disease or undergoing evaluation of cardiac anatomy for congenital heart disease
• Undergone a previous transthoracic echocardiogram within one month prior to enrollment resulting in suboptimal left ventricular endocardial border defined as ≥ 2 contiguous segments in any given view that cannot be visualized.

Exclusion Criteria

• Children < 9 years of age
• Previously enrolled in the study
• Administered any other contrast agent either intravascularly or orally within 48 hours of Lumason administration
• Known right-to-left, bidirectional or transient cardiac shunt (ruled out with agitated saline study performed before administration of Lumason)
• Known hypersensitivity to one or more of the ingredients of the investigational product
• Received an investigational compound within 30 days before enrolling into this study
• Pregnant or lactating female
• Determined by investigator to be unsuitable for the study

• Minimum Eligible Age: 9 Years
• Maximum Eligible Age: 17 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bracco Diagnostics, Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Melda Dolan, M.D.

Role: STUDY_DIRECTOR

Bracco Diagnostics, Inc

Locations

Washington University School of Medicine in Saint Louis

St Louis, Missouri, United States

University of Nebraska

Omaha, Nebraska, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

BR1-140

Identifier Type: -

Identifier Source: org_study_id